» Articles » PMID: 29053621

Isoproterenol Increases RANKL Expression in a ATF4/NFATc1-Dependent Manner in Mouse Osteoblastic Cells

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2017 Oct 21
PMID 29053621
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Sympathetic nervous system stimulation-induced β-adrenergic signal transduction is known to induce bone loss and increase of osteoclast activity. Although isoproterenol, a nonspecific β-adrenergic receptor agonist, has been shown to increase receptor activator of NF-κB ligand (RANKL), the details of the regulatory mechanisms remain unclear. In the present study, we investigated the role of the nuclear factor of activated T-cells (NFAT) in isoproterenol-induced RANKL expression in C2C12 and in primary cultured mouse calvarial cells. Isoproterenol increased nuclear factor of activated T-cells cytoplasmic 1 (NFATc1) and RANKL expressions at both mRNA and protein levels and increased NFAT reporter activity. NFATc1 knockdown blocked isoproterenol-mediated RANKL expression. Isoproterenol also promoted cAMP response element-binding protein 1 (CREB1) and activating transcription factor 4 (ATF4) phosphorylation. Isoproterenol-mediated transcriptional activation of NFAT was blocked by protein kinase A (PKA) inhibitor H89. Isoproterenol-induced CREB1, ATF4, NFATc1, and RANKL expressions were suppressed by H89. Mutations in cAMP response element-like or NFAT-binding element suppressed isoproterenol-induced promoter activity. Chromatin immunoprecipitation analysis demonstrated that isoproterenol increased NFAT-binding and ATF4-binding activities on the mouse promoter, but did not increase CREB1-binding activity. Association of NFATc1 and ATF4 was not observed in a co-immunoprecipitation study. ATF4 knockdown suppressed isoproterenol-induced NFAT binding to the promoter, whereas NFATc1 knockdown did not suppress isoproterenol-induced ATF4 binding to the promoter. ATF4 knockdown suppressed isoproterenol-induced expressions of NFATc1 and RANKL. These results suggest that isoproterenol increases RANKL expression in an ATF4/NFATc1-dependent manner.

Citing Articles

Investigating the Underlying Molecular Mechanisms of Yunke on Bone Metastases from Prostate Cancer.

Liu S, Tian Z, Zhang T, Zhang J, Huo Y, Ma C Biologics. 2024; 18:195-206.

PMID: 39071978 PMC: 11278808. DOI: 10.2147/BTT.S457188.


Osteoimmunology: The Crosstalk between T Cells, B Cells, and Osteoclasts in Rheumatoid Arthritis.

Yang M, Zhu L Int J Mol Sci. 2024; 25(5).

PMID: 38473934 PMC: 10931770. DOI: 10.3390/ijms25052688.


Deletion of a putative promoter-proximal Tnfsf11 regulatory region in mice does not alter bone mass or Tnfsf11 expression in vivo.

MacLeod R, Meyer M, Xiong J, Cawley K, Liu Y, Onal M PLoS One. 2021; 16(5):e0250974.

PMID: 33970941 PMC: 8109787. DOI: 10.1371/journal.pone.0250974.


Pregnancy and lactation, a challenge for the skeleton.

Winter E, Ireland A, Butterfield N, Haffner-Luntzer M, Horcajada M, Veldhuis-Vlug A Endocr Connect. 2020; 9(6):R143-R157.

PMID: 32438342 PMC: 7354730. DOI: 10.1530/EC-20-0055.


GATA4 represses RANKL in osteoblasts via multiple long-range enhancers to regulate osteoclast differentiation.

Khalid A, Slayden A, Kumpati J, Perry C, Berryhill S, Crawford J Bone. 2018; 116:78-86.

PMID: 30031905 PMC: 6158087. DOI: 10.1016/j.bone.2018.07.014.

References
1.
Yuvaraj S, Griffin A, Sundaram K, Kirkwood K, Norris J, Reddy S . A novel function of CXCL13 to stimulate RANK ligand expression in oral squamous cell carcinoma cells. Mol Cancer Res. 2009; 7(8):1399-407. DOI: 10.1158/1541-7786.MCR-08-0589. View

2.
Udagawa N, Takahashi N, Jimi E, Matsuzaki K, Tsurukai T, Itoh K . Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand. Bone. 1999; 25(5):517-23. DOI: 10.1016/s8756-3282(99)00210-0. View

3.
Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H . Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell. 2002; 3(6):889-901. DOI: 10.1016/s1534-5807(02)00369-6. View

4.
Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker K . Leptin regulates bone formation via the sympathetic nervous system. Cell. 2002; 111(3):305-17. DOI: 10.1016/s0092-8674(02)01049-8. View

5.
Fu Q, Manolagas S, OBrien C . Parathyroid hormone controls receptor activator of NF-kappaB ligand gene expression via a distant transcriptional enhancer. Mol Cell Biol. 2006; 26(17):6453-68. PMC: 1592840. DOI: 10.1128/MCB.00356-06. View